Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
10. Astellas, Amgen—$125M combined
10. Astellas, Amgen—$125 million combined
Takeda, Astellas-Pandion, I-Mab and more—FiercePharmaAsia
Friday, November 1, 2019
Takeda's rare disease sales dropped sharply. Astellas teamed with Pandion on Type 1 diabetes. Shanghai's I-Mab filed for a $100 million Nasdaq IPO.
Patient charities ink settlements to wrap DOJ kickback probe
Monday, October 28, 2019
An industry-wide federal probe into drugmakers' use of charity foundations to subsidize patient co-pays has netted two more settlements.
Aurobindo, Glenmark, Takeda, Ascletis and more—FiercePharmaAsia
Friday, October 11, 2019
Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.
Sanofi cuts, CEOs' Chinese names and more—FiercePharmaAsia
Friday, October 4, 2019
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Pharma companies lead Working Mother's best places to work list
Beth Snyder Bulik
Wednesday, October 2, 2019
Four of the top 10 companies on the Working Mother "100 Best Companies" annual list are pharma companies.
Eisai, Sanofi and Henlius—FiercePharmaAsia
Friday, September 20, 2019
Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.
J&J's Erleada nabs new FDA nod in metastatic prostate cancer
Wednesday, September 18, 2019
Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.
BeiGene, Sumitomo-Roivant, Roche-JHL and more—FiercePharmaAsia
Friday, September 13, 2019
BeiGene rebuffs claims that it inflated drug sales records; Sumitomo Dainippon pays $3 billion upfront for five "vants"; Genentech settles with JHL Biotech.
Astellas's first chief patient exec zeroes in on 'centricity'
Beth Snyder Bulik
Friday, September 6, 2019
Patient centricity may be a catchphrase, but with a new exec poached from Sanofi, Astellas is working to puts its money where its mouth is.